IK

IK (also called RER) encodes a 19 kDa cytokine secreted by leukemic and cancer cell lines that inhibits IFN-gamma-induced HLA class II MHC antigen expression, identified through protein purification, cDNA cloning, and antibody-mediated neutralization of its biological activity (PMID:7970704). Mechanistically, IK suppresses class II MHC expression by decreasing levels of the class II MHC transcription activator (CIITA), and a truncated form translated from an internal methionine (tIK) retains both secretion and this inhibitory activity (PMID:17075801). In MRL/lpr mice, tIK treatment reduces renal damage, T cell and macrophage infiltration, IFN-gamma and IL-2 production, and anti-DNA antibody titers, establishing that IK modulates autoimmune pathology through class II MHC-dependent suppression of immune activation (PMID:17075801). Beyond its role as an immunomodulatory cytokine, no further molecular mechanism of CIITA suppression or receptor engagement has been characterized in the available corpus.

1. 1994 High

   Established IK as a novel secreted cytokine by purifying it, cloning its cDNA, and showing transfection-driven secretion of a 19 kDa protein that neutralizably inhibits IFN-gamma-induced HLA class II expression — defining a previously unknown immunomodulatory factor with no homology to known cytokines.

   Evidence protein purification, monoclonal antibody neutralization, cDNA cloning/sequencing, COS cell transfection, and HLA-DR suppression assay in Colo 205 cells

   PMID:7970704

   Open questions at the time

   • no receptor or direct molecular target identified
   • mechanism of HLA class II suppression not resolved at this stage
   • physiological source and regulation of secretion unknown
2. 2006 Medium

   Defined the downstream mechanism and therapeutic relevance by showing a truncated IK (tIK) suppresses class II MHC via reduced CIITA expression and attenuates autoimmune renal pathology in lupus-prone mice.

   Evidence engineered truncated IK protein, transfection of fibroblastoid cells, subcutaneous injection into MRL/lpr mice, histology, flow cytometry for MHC, and ELISA for cytokines/antibodies

   PMID:17075801

   Open questions at the time

   • molecular link between secreted IK and CIITA downregulation not defined
   • no IK receptor identified to explain signal transduction
   • single-lab in vivo model
3. 2008 Low

   Implicated IK in cardiac muscle contractility, distinct from its cytokine role, via loss-of-function in a developmental model linked to a dilated cardiomyopathy locus.

   Evidence morpholino antisense knockdown of the zebrafish IK ortholog with cardiac contractility phenotyping, alongside human genetic association

   PMID:19064678

   Open questions at the time

   • single zebrafish morpholino without mammalian validation or rescue
   • no mechanistic pathway connecting IK to contractile function
   • relationship to the cytokine/MHC role unestablished

• How secreted IK molecularly engages target cells to lower CIITA, and whether its reported cardiac function reflects a distinct mechanism, remain unresolved.
• no IK receptor or direct binding partner identified
• biochemical mechanism of CIITA suppression undefined
• cardiac role not reconciled with immunomodulatory role